
Boosters: You Ask, We Answer

Swati Gaur MD, MBA, CMD, AGSF Medical Director, Post Acute Care Northeast Georgia Health System





Swati Gaur, MD, MBA, CMD, AGSF

MEDICAL DIRECTOR, POST ACUTE CARE NORTHEAST GEORGIA HEALTH SYSTEM

Dr. Swati Gaur is the medical director of New Horizons Nursing Facilities with the Northeast Georgia Health System. She is also the CEO of Care Advances Through Technology, a technology innovation company. In addition, she is on the EMR transition and implementation team for the health system, providing direction to EMR entity adaption to the LTC environment.

She has also consulted with post-acute long-term care companies on optimizing med ical services into PALTC facilities, integrating medical directors and clinicians into the QAPI framework, and creating frameworks of interdisciplinary work in the organization. In addition, Dr. Gaur established the Palliative Care Service Line at the N ortheast Georgia Health System. She also is an attending physician in several nursing f acilities. Prior to that, Dr. Gaur was a medical director at the LTC in the Carl Vinson VA Medical Center and a member of the G&EC for VISN 7.

Dr. Gaur attended medical school in Bhopal, India and did her residency in Internal Medicine at St Luke's–Roosevelt Medical Center in New York. She completed her fellowship in geriatrics at the University of Pittsburgh Medical Center and is board-certified in internal medicine, geriatrics and hospice and palliative medicine. She went on to earn her master's in business administration at Georgia Institute of Technology with a concentration in management of technology.






About Alliant Health Solutions




Omicron BA2


- Does it spread faster?
 - <u>UK Health Security Agency</u>
- BA.2 80% faster than BA.1








U.S. Wastewater Surveillance




Growth of BA2 in Our Region







Are vaccines effective against BA2

Effectiveness Against Symptomatic Disease




Effectiveness Against Hospitalization





Neutralization of the SARS -CoV-2 Omicron BA.1 and BA.2 Variants




Boosters cause


Decreased chance of catching infection

Decreased chance of transmitting infection

Decreased chance of Hospital admission

Decreased chance of death





Hause AM. Safety Monitorin g of COVID-19 Vaccine Boo ster Doses Among Adults — United States, September 22 , 2021–February 6, 2022. MM WR Morb Mortal Wkly Rep. 2 022;71. doi:10.15585/mmwr. mm7107e1

Questions?





Behavioral Health Outcomes & Opioid Misuse

- ✓ Promote opioid best practices
- Decrease high dose opioid prescribing and opioid adverse events in all settings
- ✓ Increase access to behavioral health services





Patient Safety

- ✓ Reduce risky medication combinations
- ✓ Reduce adverse drug events
- ✓ Reduce C. diff in all settings



Chronic Disease Self-Management

- ✓ Increase performance on ABCS clinical quality measures (i.e., aspirin use, blood pressure control, cholesterol management, cardiac rehab)
- ✓ Identify patients at high-risk for developing kidney disease & improve outcomes
- ✓ Identify patients at high risk for diabetes-related complications & improve outcomes



Quality of Care Transitions

- ✓ Convene community coalitions
- ✓ Identify and promote optical care for super utilizers
- ✓ Reduce community-based adverse drug events



Nursing Home Quality

- ✓ Improve the mean total quality score
- ✓ Develop national baselines for healthcare related infections in nursing homes
- ✓ Reduce emergency department visits and readmissions of short stay residents



Program Directors













This material was prepared by Alliant Health Solutions, a Quality Innovation Network – Quality Improvement Organization (QIN – QIO) and Hospital Quality Improvement Contractor (HQIC) under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services (HHS). Views expressed in this material do not necessarily reflect the official views or policy of CMS or HHS, and any reference to a specific product or entity herein does not constitute endorsement of that product or entity by CMS or HHS.

Publication No. 12SOW-AHSQIN-QIO TO1 – NH TO1 – CC-1735-03/24/22